Phase Ib Trial of Frontline Anti-CD47 Antibody Magrolimab + Azacitidine in TP53-Mutated AML

June 3-7, 2022; Chicago, Illinois
In this single-arm study, magrolimab plus azacitidine had a tolerable safety profile and achieved a CR rate of 33% in the frontline treatment of patients with TP53-mutated AML not eligible for intensive induction therapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 154 KB
Released: June 10, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
Seagen

Related Content

Experts address audience questions from a live symposium on AML treatment strategies and future therapy directions, from Clinical Care Options (CCO)

Daniel Pollyea, MD, MS
Program Director
Courtney DiNardo, MD, MSCE Eytan M. Stein, MD
Released: January 24, 2023

Clinical Care Options (CCO): Expertos repasan los principales datos sobre LLC y LCM de las juntas de ASCO, EHA, la Conferencia Pan-Pacífico sobre Linfomas, ESMO y SOHO de 2022

Othman Al-Sawaf, MD Matthew S. Davids, MD, MMSc Toby Eyre, MBChB, MD Christopher R. Flowers, MD, MS Brad S. Kahl, MD Kami Maddocks, MD Anthony Mato, MD, MSCE Lydia Scarfò, MD Julie M. Vose, MD, MBA Released: January 23, 2023

Downloadable resource designed to serve as a helpful guide for healthcare professionals on newer therapies for patients with follicular lymphoma, from Clinical Care Options (CCO)

Released: January 20, 2023

Downloadable slideset on recent advances in the clinical management of patients with CLL, from Clinical Care Options (CCO)

Jennifer R. Brown, MD, PhD Jeff Sharman, MD Released: January 19, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings